....exercising these options is purely dilutive. New financing, new CEO (no more evil Gail), new partner (Oracle), new board, new marketing director but, unfortunately, the same old product that very few physicians order. Bottom line is the company spends $13 mil a year to function and generates $1 million in sales.
New control group has vast experience with diagnostic test. OV1 has great value because its approved and proven. Based on the past experience of our new control group, OV2 will be an improved and enhanced version of the test with better financially results long term. Control your product.
Sentiment: Strong Buy
This is the big
Ms. Sacco is a proven leader in launching and building markets for innovative diagnostics to address key issues in improving women's health. She has more than 25 years of experience in product development, worldwide marketing, operations and sales management in both private and public companies. Her focus on women's health began at Centocor Diagnostics where her achievements include the U.S. launch of CA125 used to monitor ovarian cancer recurrence. More recently, she successfully led the commercial effort to build the global product market and laboratory service business for novel tests to manage pregnancy risks and infertility diagnostics as senior vice president, sales and marketing at Adeza BioMedical (acquired by Cytyc Corporation for more than $450 million, now part of Hologic).
"We are excited to add Marian's experience, energy and expertise in women's health and oncology to our team, as Vermillion expands its leadership role in commercializing OVA1 and future diagnostic tests," said Tom McLain, Vermillion's president and chief executive officer. "Marian has worked with us as a consultant in developing our commercial strategy. In this new role, she will draw on her proven track record in developing and executing sales and marketing strategies to expand awareness with physicians, patients and healthcare providers and drive increased use of OVA1."
Immediately prior to joining Vermillion, Ms. Sacco worked with numerous women's healthcare companies as a strategy and commercialization consultant. Her clients included both product and laboratory service companies focused on new, novel tests and technologies in genetics, pregnancy, reproductive health and oncology.
While at Adeza, Ms. Sacco oversaw both the strategic and day-to-day leadership of a global sales and marketing organization of more than 120 people. Over a 10-year period, her organization grew annual revenues from $1 million to $60 million and built the market for a
Ken, you are probably new to this stock. VRML has been feeding us this stuff for years, new marketing, new strategic alliances, new partnerships, new in house people. It never amounts to anything. I'm sure MS Sacco is an accomplished lady, but do you really think she will do more as an employee then she did as a paid consultant? Besides, it's got nothing to do with her, it's the product. OVA1 is a dud. Be wary of these press releases my friend, be very wary.
holt, now u got me started. vermillion refers to a list below (ONE) study done march 2011 for ova2. futher states vermillion is looking for strategic collaborations. so for over two years they been looking. all u pumpers have nothing to pump. ova2 is dead before it gets started.
Holtt, I really don't have any axe to grind here, I really don't, but if the company thinks that OVA2 might be a screening test it would have been nice to tell the shareholders as much. It's always something on the come with VRML. After Gail leaves, after we get a new board, after we get confirmation from the journals, after the Quest termination, after the Pad test comes out, after we get new financing, after OVA2, after, after, after.....